BioMarin Pharmaceutical: Expansion of VOXZOGO & Enzyme Replacement Therapy Growth Propelling Our ‘Buy’ Rating! 

BioMarin Pharmaceutical reported strong financial results for the fourth quarter and the full year of 2024. The company recorded an impressive 18% year-over-year revenue growth, reaching a total of $2.85 billion for the year. This growth was primarily driven by the strong performance of its commercial portfolio, particularly VOXZOGO for achondroplasia, which saw a 56% increase in revenue year-over-year. The company’s enzyme therapies also contributed significantly, approaching $2 billion in annual revenues with a 9% growth in the fourth quarter year-over-year.